These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10976785)

  • 21. Experimental approaches to evaluate endothelin-A receptor antagonists.
    Vatter H; Zimmermann M; Seifert V; Schilling L
    Methods Find Exp Clin Pharmacol; 2004 May; 26(4):277-86. PubMed ID: 15319806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.
    Macdonald RL
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1761-7. PubMed ID: 18922111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
    Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
    Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin receptor antagonists.
    Motte S; McEntee K; Naeije R
    Pharmacol Ther; 2006 Jun; 110(3):386-414. PubMed ID: 16219361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic implications of endothelin antagonists for cardiovascular diseases].
    Abassi Z; Ramadan R; Schwartz H; Hoffman A
    Harefuah; 2004 Jan; 143(1):47-53, 84. PubMed ID: 14748289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan in essential hypertension.
    Haynes WG; Ferro CJ; Webb DJ
    N Engl J Med; 1998 Jul; 339(5):346; author reply 347. PubMed ID: 9696644
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins.
    Sütsch G; Bertel O; Rickenbacher P; Clozel M; Yandle TG; Nicholls MG; Kiowski W
    Am J Cardiol; 2000 Apr; 85(8):973-6. PubMed ID: 10760337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist.
    Zimmermann M; Seifert V; Löffler BM; Stolke D; Stenzel W
    Neurosurgery; 1996 Jan; 38(1):115-20. PubMed ID: 8747959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists.
    Zuccarello M; Soattin GB; Lewis AI; Breu V; Hallak H; Rapoport RM
    J Neurosurg; 1996 Mar; 84(3):503-7. PubMed ID: 8609565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
    Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP
    Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P; Amoura Z; Langleben D
    Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversing congestive heart failure with endothelin receptor antagonists.
    Yazaki Y; Yamazaki T
    Circulation; 1997 Apr; 95(7):1752-4. PubMed ID: 9107157
    [No Abstract]   [Full Text] [Related]  

  • 35. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition.
    Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR
    Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
    New RB; Sampson AC; King MK; Hendrick JW; Clair MJ; McElmurray JH; Mandel J; Mukherjee R; de Gasparo M; Spinale FG
    Circulation; 2000 Sep; 102(12):1447-53. PubMed ID: 10993866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
    Sütsch G; Kiowski W; Yan XW; Hunziker P; Christen S; Strobel W; Kim JH; Rickenbacher P; Bertel O
    Circulation; 1998 Nov; 98(21):2262-8. PubMed ID: 9826312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of endothelin receptor antagonists on vasospasm following aneurysmal subarachnoid hemorrhage.
    Komotar RJ; Starke RM; Connolly ES
    Neurosurgery; 2011 Dec; 69(6):N13-4. PubMed ID: 22067343
    [No Abstract]   [Full Text] [Related]  

  • 39. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis.
    Kramer A; Fletcher J
    Stroke; 2009 Oct; 40(10):3403-6. PubMed ID: 19679843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin receptor blockade in congestive heart failure.
    Cheng TO
    Circulation; 2001 Oct; 104(18):E96. PubMed ID: 11684644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.